Advanced Cell Diagnostics, Inc.
Newark, CA Part of Bio-Techne Corporation
- UEI
- UD6XW8DAGLK6
- CAGE
- 4FBA8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
RDJKATCM39L5
-
Parent
RDJKATCM39L5
- SAM.gov registration date
- Physical address
- 7707 Gateway Blvd #200, Newark, CA 94560, USA
- Website
- acdbio.com
- Founded
- 2006
- Employees
- 51-250
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $374,514 |
| FY2025 | $123,145 |
| FY2024 | $192,773 |
| FY2023 | $529,501 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $384,069 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Similar vendors
About the company
Advanced Cell Diagnostics, Inc., a subsidiary of Bio-Techne Corporation, manufactures RNA detection reagents, assays, probes, and automated imaging systems for federal biomedical research as a prime contractor in full-and-open competition, without set-aside designations. Based in Newark, California, Advanced Cell Diagnostics operates under NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and related biotechnology codes, delivering its proprietary RNAscope platform and COMET automated sequential immunofluorescence imaging systems to support research across the National Institutes of Health and affiliated federal agencies.
The company's customer base concentrates heavily within NIH's intramural research enterprise. By award count, the top five customers account for 45% of recent awards and are dominated by the National Institute on Drug Abuse (24 awards, $358 thousand combined potential value), the National Institute of Allergy and Infectious Diseases (20 awards, $355 thousand), and the NIH Clinical Center (11 awards, $314 thousand). By potential value, however, the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1 ranks first ($897 thousand across 8 awards), followed by the National Heart, Lung and Blood Institute ($488 thousand across 4 awards). This divergence reflects Advanced Cell Diagnostics' role as a sole-source supplier of specialized molecular diagnostics products to multiple NIH institutes on small, repeat purchase orders alongside occasional larger system procurements through the VA.
Representative work includes a $399.8 thousand purchase order from the National Heart, Lung and Blood Institute (July 2026) for the COMET Package—an automated sequential immunofluorescence staining and imaging system for spatial multiomics analysis supporting lung biology and transplant injury research; a $94.1 thousand firm-fixed-price order from the National Institute on Drug Abuse (August 2023) for RNAscope HiPlex mouse RNA probes; and a $24.7 thousand sole-source award from the Department of Veterans Affairs (September 2025) for RNA Scope multiplex RNA in situ hybridization assays and reagents to support neuropathology research at the VA Medical Center in Providence, Rhode Island. Across the portfolio, Advanced Cell Diagnostics holds 100% prime awards with zero subcontracting activity.
Recent activity has declined sharply. The vendor received 13 awards in 2022, 21 in 2023, 10 in 2024, 6 in 2025, and 1 in 2026, reflecting a tightening of repeat orders. One award (the NHLBI COMET system) with combined potential value of $400 thousand reaches ultimate completion within the next twenty-four months, presenting moderate recompete exposure. Advanced Cell Diagnostics sits on Indefinite Delivery Contract 36C24E18D0050 with 5 task orders valued at $119 thousand. The portfolio spans 172 total awards to 36 distinct federal agencies since 2006, with combined potential value of $3.7 million but combined obligated dollars of $8.4 million, indicating substantial contract modifications and re-obligations over the source period. Award types are uniformly purchase orders—no IDIQs, GWACs, or vehicles beyond the single IDC noted above. All awards are full-and-open, non-set-aside procurements reflecting Advanced Cell Diagnostics' status as the exclusive manufacturer of RNAscope and related proprietary technologies that support NIH's core research infrastructure.
Quick answers
Is Advanced Cell Diagnostics, Inc. registered in SAM.gov?
Yes. Advanced Cell Diagnostics, Inc.'s SAM.gov registration is active through January 12, 2027.
How much has Advanced Cell Diagnostics, Inc. received in federal contracts?
Federal contracts obligated $123,145 to Advanced Cell Diagnostics, Inc. in fiscal year 2025 and $1,219,933 in fiscal years 2023 through 2027.
What is Advanced Cell Diagnostics, Inc.'s most recent federal award?
Advanced Cell Diagnostics, Inc.'s most recent federal contract award is Nhlbi: supply: comet package: automated seqif stainer and imaging system for spatial multiomics analysis (75N98026P01060), from Office of Logisitics and Acquisition Operations (NIH), on July 20, 2026.
On GovTribe
See Advanced Cell Diagnostics, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors